Korean Journal of Audiology (대한청각학회지)

The Korean Audiology Society (대한청각학회)
권호 표지
DOI QR코드

DOI QR Code

Cochlear Implantation via the Transmeatal Approach in an Adolescent with Hunter Syndrome-Type II Mucopolysaccharidosis

  • Kim, Hantai (Department of Otolaryngology, Ajou University School of Medicine) ;
  • An, Jun Young (Department of Otolaryngology, Ajou University School of Medicine) ;
  • Choo, Oak-Sung (Department of Otolaryngology, Ajou University School of Medicine) ;
  • Jang, Jeong Hun (Department of Otolaryngology, Ajou University School of Medicine) ;
  • Park, Hun Yi (Department of Otolaryngology, Ajou University School of Medicine) ;
  • Choung, Yun-Hoon (Department of Otolaryngology, Ajou University School of Medicine)
  • Received : 2019.08.01
  • Accepted : 2019.10.21
  • Published : 2021.01.20
⟨ Previous Next ⟩

Abstract

Type II mucopolysaccharidosis (MPS II) commonly known as Hunter syndrome, is a rare X-linked lysosomal storage disorder caused by iduronate-2-sulfatase deficiency, which in turn causes otorhinolaryngological manifestations, including sensorineural hearing loss (SNHL). Previously, the median survival age of patients with MPS was approximately 13.4 years. However, in the era of enzyme replacement therapy and other multidisciplinary care modalities, the life expectancy has increased. Herein, we report a rare case of an adolescent with MPS II who underwent SNHL treatment with cochlear implantation (CI). Based on unexpected findings of mastoid emissary veins and overgrowth of the vessels around the temporal bone, CI was performed using the transmeatal approach instead of the conventional transmastoid method, to avoid damage to the vessels. The average hearing threshold after CI was 35 dB and no surgical complications were encountered. Adolescent MPS II may present vessel abnormalities, which can reduce the success rate of surgery. In patients with MPS II with SNHL, CI should be performed under careful monitoring of vessel overgrowth. Moreover, with regard to feasibility of CI in adolescent patients with MPS II with SNHL, surgical techniques such as the transmeatal approach should be selected based on adequate assessment of the case.

Keywords

References

  1. Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 2005;69:589-95. https://doi.org/10.1016/j.ijporl.2005.01.017
  2. Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28:1011-7. https://doi.org/10.1007/s10545-005-0112-z
  3. Keilmann A, Nakarat T, Bruce IA, Molter D, Malm G; HOS Investigators. Hearing loss in patients with mucopolysaccharidosis II: data from HOS - The Hunter Outcome Survey. J Inherit Metab Dis 2012;35:343-53. https://doi.org/10.1007/s10545-011-9378-5
  4. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167:267-77. https://doi.org/10.1007/s00431-007-0635-4
  5. Da Costa V, O'Grady G, Jackson L, Kaylie D, Raynor E. Improvements in sensorineural hearing loss after cord blood transplant in patients with mucopolysaccharidosis. Arch Otolaryngol Head Neck Surg 2012;138:1071-6. https://doi.org/10.1001/jamaoto.2013.597
  6. Lin HY, Shih SC, Chuang CK, Lee KS, Chen MR, Lin HC, et al. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses. Mol Genet Metab 2014;111:533-8. https://doi.org/10.1016/j.ymgme.2014.02.003
  7. Saeed H, Nichani J, Melling C, Raine CH, Khan I, Martin JM, et al. Feasibility of cochlear implantation in Mucopolysaccharidosis. Int J Pediatr Otorhinolaryngol 2013;77:1255-8. https://doi.org/10.1016/j.ijporl.2013.05.003
  8. Taibah K. The transmeatal approach: a new technique in cochlear and middle ear implants. Cochlear Implants Int 2009;10:218-28. https://doi.org/10.1179/cim.2009.10.4.218
  9. Kronenberg J, Migirov L, Baumgartner WD. The suprameatal approach in cochlear implant surgery: our experience with 80 patients. ORL J Otorhinolaryngol Relat Spec 2002;64:403-5. https://doi.org/10.1159/000067576
  10. Mitchell J, Berger KI, Borgo A, Braunlin EA, Burton BK, Ghotme KA, et al. Unique medical issues in adult patients with mucopoly-saccharidoses. Eur J Intern Med 2016;34:2-10. https://doi.org/10.1016/j.ejim.2016.05.017
  11. Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2009;32:534-43. https://doi.org/10.1007/s10545-009-1119-7
  12. Friedmann DR, Amoils M, Germiller JA, Lustig LR, Glastonbury CM, Pramanik BK, et al. Venous malformations of the temporal bone are a common feature in CHARGE syndrome. Laryngoscope 2012;122:895-900. https://doi.org/10.1002/lary.23205
  13. Ganaha A, Tono T, Kaname T, Yanagi K, Higa T, Kondo S, et al. Suprameatal cochlear implantation in a CHARGE patient with a novel CHD7 variant and KALLMANN syndrome phenotype: a case report. Otol Neurotol 2017;38:990-5. https://doi.org/10.1097/mao.0000000000001481
  14. Wang RY, Braunlin EA, Rudser KD, Dengel DR, Metzig AM, Covault KK, et al. Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness. Mol Genet Metab 2014;111:128-32. https://doi.org/10.1016/j.ymgme.2013.11.001
  15. Tanyildizi Y, Gokce S, Marini F, Mayer AK, Kirschner S, Hennermann JB, et al. Vessel shape alterations of the vertebrobasilar arteries in Mucopolysaccharidosis type IVa (Morquio A) patients. Eur J Radiol 2017;93:128-33. https://doi.org/10.1016/j.ejrad.2017.05.026